New hope for tough cancers: experimental drug targets HER3 in advanced tumors
NCT ID NCT06956690
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called HMBD-501 in 180 adults with advanced solid tumors (melanoma, lung, or breast cancer) that have a protein called HER3 on their cells and have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then checking if the drug can shrink tumors. The goal is to control the disease, not cure it, as patients may need ongoing treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGLa Jolla, California, 92093, United States
-
Research Site
RECRUITINGIndianapolis, Indiana, 46250, United States
-
Research Site
RECRUITINGFarmington Hills, Michigan, 48334, United States
-
Research Site
RECRUITINGDallas, Texas, 75230, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
Research Site
WITHDRAWNCampbelltown, New South Wales, 2560, Australia
-
Research Site
WITHDRAWNMiranda, New South Wales, 2228, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Radiation may let breast cancer patients keep their nipple